Abbott Laboratories (NYSE:ABT) is one of the
7 Best Longevity Stocks to Buy Now.
On June 7, 2026, Abbott Laboratories (NYSE:ABT) announced new data showing that diabetic ketoacidosis, or DKA, “remains an important” but often undetected health concern for people with both Type 1 and Type 2 diabetes. The findings, shared at the American Diabetes Association’s 86th Scientific Sessions, showed sharp increases in DKA-related hospitalizations across all age groups nationwide. Mahmood Kazemi, chief medical officer for Abbott’s diabetes care business, said the data show that preventing DKA starts with recognizing risk earlier.
Africa Studio/Shutterstock.com
On May 27, 2026, Abbott Laboratories (NYSE:ABT) announced that it secured the CE Mark for its dual glucose-ketone sensing technology for people with diabetes. Branded as Libre Duo and Libre Duo 10 Day, the systems are designed to continuously measure glucose and ketone levels every minute, giving users real-time visibility into glucose levels and rising ketones that can lead to a DKA emergency. Abbott said it plans to begin launching Libre Duo systems in select European countries later this year.
Also on May 27, Abbott said the American Cancer Society released updated colorectal cancer screening guidelines that reaffirm Cologuard and Cologuard Plus as preferred noninvasive screening options for adults aged 45 and older at average risk for CRC.
Abbott Laboratories (NYSE:ABT) discovers, develops, manufactures, and sells health care products worldwide.
While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.
